Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma
Matthew M. Weiss, Xiaozhang Zheng, Nan Ji, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 10548-10566
Closed Access | Times Cited: 12

Showing 12 citing articles:

Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
Xiaozhang Zheng, Nan Ji, Veronica A. Campbell, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18022-18037
Open Access | Times Cited: 10
Spirocyclic compounds as innovative tools in drug discovery for medicinal chemists
Marina T. Varela, Gleiston G. Dias, Luiz Fernando N. de Oliveira, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117368-117368
Closed Access | Times Cited: 1
Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects
Yaoxiang Lin, Lulu Zheng, Ying Xu, et al.
Journal of Medicinal Chemistry (2025) Vol. 68, Iss. 2, pp. 902-914
Closed Access
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Advancements in PROTAC-based therapies for neurodegenerative diseases
Deyuan Kong, Liying Meng, Pengfei Lin, et al.
Future Medicinal Chemistry (2025), pp. 1-15
Closed Access
Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs
Yifan Feng, Chengjuan Chen, Anqi Shao, et al.
Chinese Chemical Letters (2025), pp. 110963-110963
Closed Access
Diversity Synthesis Using Glutarimides as Rhodium Carbene Precursors in Enantioselective C–H Functionalization and Cyclopropanation
William F. Tracy, Jack C. Sharland, Duc Ly, et al.
Journal of the American Chemical Society (2025)
Open Access
Recent advances in PROTAC-based antiviral and antibacterial therapeutics
Can Zhou, Shiwei Yang, Jun Wang, et al.
Bioorganic Chemistry (2025), pp. 108437-108437
Closed Access
The Latest Advancements of the PROTACs Based on CRBN E3 Ligase for Cancer Treatment
V. O. Stadnichenko, Petro Borysko, Ganna Tolstanova
Current Pharmacology Reports (2025) Vol. 11, Iss. 1
Closed Access
Property-based optimisation of PROTACs
James S. Scott, Iacovos N. Michaelides, Markus Schade
RSC Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Therapeutic potential of isoniazid carbohydrazide derivatives as a promising anti-inflammatory and anti-diabetic drug via synthesis, characterization, biological screening, and computational studies
Krishnakumar Ranganathan, Meenakshi Srinivasan, Maqusood Ahamed, et al.
Journal of Molecular Structure (2024), pp. 141106-141106
Closed Access | Times Cited: 1
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)
Xiang Fei
Expert Opinion on Therapeutic Patents (2024)
Closed Access | Times Cited: 1
Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474
Scott D. Edmondson
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18017-18021
Closed Access
Page 1

Scroll to top